KMT2A and leukemia: While KMT2A-r leukemias are unified by an aggressive clinical disease course characterized by treatment resistance, other factors such as the specific KMT2A translocation, particular gene breakpoints, and age of the patient actually define different disease subtypes driven by diverse leukemogenic pathways (25–27).